Table 1.
Baseline characteristics.
| Characteristic | Total (N = 105) | Zercepac (n = 65) | Reference trastuzumab (n = 40) | P |
|---|---|---|---|---|
| Age, years, mean ± SD | 48.73 ± 9.11 | 48.48 ± 9.28 | 49.15 ± 8.93 | 0.715 |
|
| ||||
| Sex, n (%) | ||||
| Female | 105 (100.0) | 65 (100.0) | 40 (100.0) | |
| Male | 0 | 0 | 0 | |
|
| ||||
| BMI, kg/m2, median (range) | 23.20 (19.40, 26.50) | 22.40 (19.40, 26.50) | 23.40 (19.62, 26.47) | 0.877 |
|
| ||||
| Menstruation situation, n (%) | 0.658 | |||
| Premenopausal | 47 (44.8) | 28 (43.1) | 19 (47.5) | |
| Postmenopausal | 58 (55.2) | 37 (56.9) | 21 (52.5) | |
|
| ||||
| Histological typing, n (%) | ||||
| Invasive carcinoma | 105 (100.0) | 65 (100.0) | 40 (100.0) | |
| Other | 0 | 0 | 0 | |
|
| ||||
| Histological grading, n (%) | 0.060∗ | |||
| Grade 1 | 5 (4.8) | 3 (4.6) | 2 (5.0) | |
| Grade 2 | 35 (33.3) | 27 (41.5) | 8 (20.0) | |
| Grade 3 | 65 (61.9) | 35 (53.8) | 30 (75.0) | |
|
| ||||
| Time from diagnosis to trastuzumab treatment, days, media (range) | 6 (4, 9) | 6 (4, 12) | 6 (4, 8) | 0.691 |
|
| ||||
| HER2 status, n (%) | ||||
| - | 0 | 0 | 0 | |
| + | 105 (100.0) | 65 (100.0) | 40 (100.0) | |
|
| ||||
| ER status, n (%) | 0.728 | |||
| - | 45 (42.9) | 27 (41.5) | 18 (45.0) | |
| + | 60 (57.1) | 38 (58.5) | 22 (55.0) | |
|
| ||||
| PR status, n (%) | 0.059 | |||
| - | 67 (63.8) | 46 (70.8) | 21 (52.5) | |
| + | 38 (36.2) | 19 (29.2) | 19 (47.5) | |
|
| ||||
| Molecular typing, n (%) | 0.799 | |||
| HER2+HR- | 41 (39.0) | 26 (40.0) | 15 (37.5) | |
| HER2+HR+ | 64 (61.0) | 39 (60.0) | 25 (62.5) | |
|
| ||||
| Ki67, %, median (range) | 40.00 (40.00, 60.00) | 50.00 (40.00, 60.00) | 40.00 (30.00, 50.00) | 0.026 |
| Maximum tumor diameter, mm, median (range) | 24.00 (18.00, 33.00) | 24.00 (18.00, 34.00) | 22.00 (18.75, 32.00) | 0.815 |
| NLR, median (range) | 2.67 (1.78, 3.56) | 2.57 (1.88, 3.56) | 2.72 (1.64, 3.48) | 0.779 |
| PLR, median (range) | 179.41 (137.73, 219.43) | 174.61 (137.28, 218.39) | 191.96 (139.06, 228.33) | 0.409 |
BMI—Body mass index; HER2—human epidermal growth factor receptor 2; ER—estrogen receptors; PR—progesterone receptors; NLR—neutrophil-to-lymphocyte ratio; PLR—platelet-lymphocyte ratio; SD—standard deviation.